About the company
Sava is a London-based biotech building wearable biosensing technology aimed at pulling “deep health data” from just below the skin, with an early focus on continuous glucose monitoring. The company states the biosensor is still investigational and not yet approved by regulators such as the UK MHRA or the US FDA. Recent public coverage links Sava to a Series A raise in 2025 tied to clinical progress in glucose monitoring. The company’s hiring skews heavily toward hardware, manufacturing, and data roles consistent with a device team moving from R&D into build and test.